Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study
复制标题
DOI：
10.1086/318829
复制
发表时间：
2001-03-01
影响因子：
6.4
通讯作者：
Hatz, MH
中科院分区：
文献类型：
--
作者：
Kahn, JO;Martin, JN;Hatz, MH
评估了在性行为或注射吸毒暴露于人类免疫缺陷病毒 (HIV) 后提供暴露后预防 (PEP) 的可行性。在 72 小时内向那些与已知患有 HIV 或有感染 HIV 风险的伴侣接触过的个人提供 PEP。 PEP 包括 4 周的抗逆转录病毒药物治疗以及个性化的风险降低和药物依从咨询。在 401 名寻求 PEP 的参与者中，性接触最为常见（94%；n = 375）。在性接触中，接受性（40%）和插入性（27%）肛交是最常见的性行为。从暴露到治疗的中位时间为 33 小时。 97% 的参与者仅接受双重逆转录酶抑制剂治疗，78% 的参与者完成了 4 周的治疗。暴露后 6 个月，没有参与者产生 HIV 抗体，尽管为 12% 的参与者提供了针对随后暴露的第二次 PEP 课程。非职业性 HIV 暴露后，PEP 对于有 HIV 感染风险的人来说是可行的。
The feasibility of providing postexposure prophylaxis (PEP) after sexual or injection drug use exposures to human immunodeficiency virus (HIV) was evaluated. PEP was provided within 72 h to individuals with exposures from partners known to have or to be at risk for HIV infection. PEP consisted of 4 weeks of antiretroviral medications and individually tailored risk-reduction and medication-adherence counseling. Among 401 participants seeking PEP, sexual exposures were most common (94%; n = 375). Among sexual exposures, receptive (40%) and insertive (27%) anal intercourse were the most common sexual acts. The median time from exposure to treatment was 33 h. Ninety-seven percent of participants were treated exclusively with dual reverse-transcriptase inhibitors, and 78% completed the 4-week treatment. Six months after the exposure, no participant developed HIV antibodies, although a second PEP course for a subsequent exposure was provided to 12%. PEP, after nonoccupational HIV exposure, is feasible for persons at risk for HIV infection.